Clinical trials
Resistant Cancer clinical trials
Below are recruiting resistant cancer clinical trials, each written for real people, not researchers. We’re tracking 403 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06829459RecruitingPhase 3
New drug combo vs chemo for resistant lung cancer
This trial tests a combination of two targeted drugs (Glumetinib and Osimertinib) against standard chemotherapy for people with non-small cell lung cancer that has stopped responding to initial targeted therapy. It may be an option if your tumor has a specific genetic change called MET amplification or overexpression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05818683RecruitingPhase 1
Pasritamig plus other drugs for advanced prostate cancer
This Phase 1 study tests pasritamig (JNJ-78278343) combined with other prostate cancer treatments in people with advanced prostate cancer that has spread. It aims to find the safest dose and see whether the combinations can help slow the cancer.
Sarasota, FloridaAges 18 years+ - NCT04918186RecruitingPhase 2
Immunotherapy for platinum-resistant ovarian, with tumor testing
This Phase 2 study tests an immunotherapy approach for women whose high-grade serous ovarian cancer came back within 6 months of platinum chemotherapy. It may help shrink tumors and improve control of the disease, but you’ll need tumor biopsies and lab/heart/lung checks to join.
Chicago, IllinoisAges 18 years+ - NCT06472245RecruitingPhase 3
Cancer vaccine for lung cancer that stopped responding to immunotherapy
This trial tests a therapeutic cancer vaccine called OSE2101 for people with advanced non-small cell lung cancer whose tumors stopped responding to an immunotherapy drug. The vaccine is designed to help your immune system fight the cancer in a different way.
Beverly Hills, CaliforniaAges 18 years+ - NCT06687070RecruitingPhase 1
APG-2449 alone or with PLD for advanced cancers
This trial tests a new drug, APG-2449, either alone or with another chemotherapy called PLD (pegylated liposomal doxorubicin). It is for people with advanced solid tumors, including ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is.
Guangzhou, GuangdongAges 18 years+ - NCT05601440RecruitingPhase 2
Trial for metastatic breast cancer that resisted CDK4/6 treatment
This Phase 2 study tests treatments guided by blood testing (“liquid biopsy”) in people with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed after standard CDK4/6 medicine plus hormone therapy. It aims to find a better way to control cancer after the first treatment stops working.
Calgary, AlbertaAges Any age - NCT07543055RecruitingPhase 1
CAR T-Cell Therapy for Advanced Prostate Cancer
This trial tests BPX-601, a new type of cell therapy that uses your own immune cells to fight prostate cancer that has spread and stopped responding to hormone treatments. The study aims to see if this approach can help men whose cancer has returned despite multiple prior treatments.
Hackensack, New JerseyAges 18 years+ - NCT04363164RecruitingPhase 2
Testosterone then enzalutamide to stop prostate cancer spread
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
San Diego, CaliforniaAges 18–90 - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Birmingham, AlabamaAges 18 years+ - NCT06994195RecruitingPhase 3
Comparing an experimental drug to standard chemo for ovarian cancer
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07217301RecruitingPhase 3
Comparing TAK-928 to docetaxel for advanced lung cancer
This study tests a new drug called TAK-928 against the standard chemo docetaxel for people with advanced squamous non-small cell lung cancer. You may be able to join if you have already tried a checkpoint inhibitor and platinum chemotherapy, and your cancer has grown.
Jonesboro, ArkansasAges 18 years+ - NCT04518501RecruitingPhase 1/Phase 2
Testing fuzuloparib with arsenic and platinum for ovarian cancer
This early-phase study tests a combination of three medicines to treat ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum chemotherapy, especially when tumors have a BRCA1 or BRCA2 mutation. The goal is to see if this treatment can help control cancer that is hard to treat.
Zhejiang, HangzhouAges 18–70 - NCT05690048RecruitingPhase 2
Fecal transplant to help liver cancer respond to standard drugs
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07463092Recruiting
Creatine and exercise for muscle health in prostate cancer
This study tests whether taking creatine and doing weightlifting exercises can help men with prostate cancer who have been on hormone therapy for at least 6 months to improve muscle strength and size. It lasts 12 weeks and involves supervised workouts three times per week.
São Paulo, São PauloAges 40 years+ - NCT05116137Enrolling by invitation
Exercise therapy to build muscle after glioblastoma
This trial studies whether a resistance (strength-building) exercise program can help survivors of glioblastoma keep or increase their muscle mass. If you are able to safely exercise, it may support recovery and overall strength after treatment.
Halifax, Nova ScotiaAges 18 years+ - NCT07737509Recruiting
Understanding genetic factors in advanced solid tumor treatment
This study collects and analyzes tumor samples from people with advanced solid cancers to understand why some treatments work better than others and why resistance can develop. It aims to improve future treatments for patients like you.
SuttonAges 18 years+ - NCT07465393Recruiting
Facility rehab vs home exercise for breast cancer survivors
This trial compares two types of exercise programs for breast cancer survivors to see which one improves quality of life more. You will either attend supervised rehab sessions at a facility or follow a resistance exercise program at home.
New Taipei City, Xindian DistAges 18 years+ - NCT07181499RecruitingPhase 2
Chemotherapy with befotertinib for resistance to targeted lung cancer drugs
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
Guangzhou, GuangdongAges 18 years+ - NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Springdale, ArkansasAges 18–90 - NCT07278440Recruiting
Exercise program for brain tumor patients and their partners
This study tests if a home exercise program can improve mental and physical health for people with brain tumors and their live-in partners. Both of you will be guided through exercise sessions together over video.
Portland, OregonAges 18 years+ - NCT06646627RecruitingPhase 1
B7-H3 car t cells for platinum-resistant ovarian cancer
This trial tests a new treatment where your own immune cells are modified to attack ovarian cancer cells that have stopped responding to platinum chemotherapy. It's for people with recurrent ovarian cancer that hasn't gotten better with standard treatments.
Palo Alto, CaliforniaAges 18 years+ - NCT07203378RecruitingPhase 2
Exercise program to boost energy on Enhertu
This trial tests if a guided exercise program can help reduce fatigue and improve energy for people with breast cancer who are taking the drug Enhertu. You would do both aerobic and resistance exercises as part of the study.
Salt Lake City, UtahAges 18 years+ - NCT01580982Recruiting
Analyze tumor genetic changes to understand lung cancer resistance
This study looks at lung cancer tumor tissue to find genetic “on/off” changes and why treatments may stop working. It may help your care team choose better next tests or treatments based on what the tumor is doing.
Aurora, ColoradoAges 18–85
Hear when a new Resistant Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resistant cancer?
- Yes. Clin2 currently lists 403 recruiting resistant cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resistant cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resistant cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Non Small Cell Lung Cancer
- Castration-resistant Prostate Cancer
- Platinum-resistant Ovarian Cancer
- Castrate Resistant Prostate Cancer
- Gastric Cancer, Gastroesophageal Junction Cancer
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.